Drugs / Satori-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04729582 | Jun 2024 → Aug 2026 overdue | epispadias, urethral intrinsic sphincter deficiency | Simone Spuler, MD | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Satori-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04729582 ↗ |
| Action | Restore | “with the aim of repairing the defect and restore the anatomic ability for continence” NCT04729582 ↗ |
| Modality | Cell therapy | “autologous muscle stem cell therapy” NCT04729582 ↗ |
| Route | Other | “They are injected into the urethral sphincter region as a one-time autologous treatment.” NCT04729582 ↗ |